KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Xylem (XYL) EPS (Weighted Average and Diluted) (2016 - 2025)

Historic EPS (Weighted Average and Diluted) for Xylem (XYL) over the last 16 years, with Q3 2025 value amounting to $0.93.

  • Xylem's EPS (Weighted Average and Diluted) rose 449.44% to $0.93 in Q3 2025 from the same period last year, while for Sep 2025 it was $3.88, marking a year-over-year increase of 1149.43%. This contributed to the annual value of $3.63 for FY2024, which is 3025.75% up from last year.
  • As of Q3 2025, Xylem's EPS (Weighted Average and Diluted) stood at $0.93, which was up 449.44% from $0.93 recorded in Q2 2025.
  • Xylem's 5-year EPS (Weighted Average and Diluted) high stood at $1.32 for Q4 2024, and its period low was $0.07 during Q3 2022.
  • For the 5-year period, Xylem's EPS (Weighted Average and Diluted) averaged around $0.7, with its median value being $0.63 (2021).
  • In the last 5 years, Xylem's EPS (Weighted Average and Diluted) tumbled by 8888.89% in 2022 and then skyrocketed by 80000.0% in 2023.
  • Quarter analysis of 5 years shows Xylem's EPS (Weighted Average and Diluted) stood at $0.62 in 2021, then surged by 32.26% to $0.82 in 2022, then soared by 41.46% to $1.16 in 2023, then increased by 13.63% to $1.32 in 2024, then fell by 29.45% to $0.93 in 2025.
  • Its EPS (Weighted Average and Diluted) stands at $0.93 for Q3 2025, versus $0.93 for Q2 2025 and $0.69 for Q1 2025.